Nishigaya Yosuke, Umei Kentaro, Saito Yoshifumi, Watanabe Hiroyuki, Kondo Tatsuhiro, Kondo Atsushi, Kawamura Naohiro, Tatani Kazuya, Kohno Yasushi, Tanaka Nobuyuki, Seto Shigeki
Watarase Research Center, Discovery Research Headquarters, Kyorin Pharmaceutical Co., Ltd., 1848, Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.
Central Research Laboratories, Kissei Pharmaceutical Co., Ltd., 4365-1, Kashiwabara, Hotaka, Azumino, Nagano 399-8304, Japan.
Bioorg Med Chem Lett. 2017 Sep 1;27(17):4044-4050. doi: 10.1016/j.bmcl.2017.07.055. Epub 2017 Jul 25.
A scaffold-hopping strategy towards a new pyrazolo[1,5-a]pyridine based core using molecular hybridization of two structurally distinct EP antagonists, followed by structure-activity relationship-guided optimization, resulted in the identification of potent EP antagonists exemplified by 4c, 4f, and 4j, which were shown to reduce pathological intravesical pressure in rats when administered at 1mg/kg iv.
通过两种结构不同的EP拮抗剂的分子杂交,采用骨架跳跃策略构建基于新型吡唑并[1,5 - a]吡啶的核心结构,随后在构效关系指导下进行优化,得到了以4c、4f和4j为代表的强效EP拮抗剂,静脉注射1mg/kg时,这些拮抗剂可降低大鼠膀胱内病理性压力。